Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
6 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
VRK1 Is a Synthetic-Lethal Target in VRK2-Deficient Glioblastoma.
Cancer Res. 2022 Nov 2;82(21):4044-4057. doi: 10.1158/0008-5472.CAN-21-4443.
Cancer Res. 2022.
PMID: 36069976
Free PMC article.
A 27-amino-acid synthetic peptide corresponding to the NH2-terminal zinc-binding domain of endostatin is responsible for its antitumor activity.
Tjin Tham Sjin RM, Satchi-Fainaro R, Birsner AE, Ramanujam VM, Folkman J, Javaherian K.
Tjin Tham Sjin RM, et al.
Cancer Res. 2005 May 1;65(9):3656-63. doi: 10.1158/0008-5472.CAN-04-1833.
Cancer Res. 2005.
PMID: 15867360
Item in Clipboard
Linking antibody Fc domain to endostatin significantly improves endostatin half-life and efficacy.
Lee TY, Tjin Tham Sjin RM, Movahedi S, Ahmed B, Pravda EA, Lo KM, Gillies SD, Folkman J, Javaherian K.
Lee TY, et al. Among authors: tjin tham sjin rm.
Clin Cancer Res. 2008 Mar 1;14(5):1487-93. doi: 10.1158/1078-0432.CCR-07-1530.
Clin Cancer Res. 2008.
PMID: 18316573
Item in Clipboard
Endostatin therapy reveals a U-shaped curve for antitumor activity.
Tjin Tham Sjin RM, Naspinski J, Birsner AE, Li C, Chan R, Lo KM, Gillies S, Zurakowski D, Folkman J, Samulski J, Javaherian K.
Tjin Tham Sjin RM, et al.
Cancer Gene Ther. 2006 Jun;13(6):619-27. doi: 10.1038/sj.cgt.7700938.
Cancer Gene Ther. 2006.
PMID: 16456550
Item in Clipboard
Two Endogenous Antiangiogenic Inhibitors, Endostatin and Angiostatin, Demonstrate Biphasic Curves in their Antitumor Profiles.
Javaherian K, Lee TY, Tjin Tham Sjin RM, Parris GE, Hlatky L.
Javaherian K, et al. Among authors: tjin tham sjin rm.
Dose Response. 2011;9(3):369-76. doi: 10.2203/dose-response.10-020.Javaherian. Epub 2010 Oct 21.
Dose Response. 2011.
PMID: 22013399
Free PMC article.
Item in Clipboard
In vitro and in vivo characterization of irreversible mutant-selective EGFR inhibitors that are wild-type sparing.
Tjin Tham Sjin R, Lee K, Walter AO, Dubrovskiy A, Sheets M, Martin TS, Labenski MT, Zhu Z, Tester R, Karp R, Medikonda A, Chaturvedi P, Ren Y, Haringsma H, Etter J, Raponi M, Simmons AD, Harding TC, Niu D, Nacht M, Westlin WF, Petter RC, Allen A, Singh J.
Tjin Tham Sjin R, et al.
Mol Cancer Ther. 2014 Jun;13(6):1468-79. doi: 10.1158/1535-7163.MCT-13-0966. Epub 2014 Apr 10.
Mol Cancer Ther. 2014.
PMID: 24723450
Item in Clipboard
Cite
Cite